Drug Profile
DHP 1401
Alternative Names: DHP-1401Latest Information Update: 23 Feb 2022
Price :
$50
*
At a glance
- Originator DAE HWA Pharmaceutical
- Class
- Mechanism of Action AMPA receptor modulators; Mitogen-activated protein kinase modulators; Protein kinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 23 Feb 2022 Discontinued - Phase-II for Alzheimer's disease (In the elderly, In adults) in South Korea (PO) (DAE HWA Pharmaceutical pipeline, February 2022)
- 28 Feb 2019 Daehwa Pharmaceutical completes the phase IIb DRAMA trial in Alzheimer's disease (In adults, In the elderly) in South Korea (PO) (NCT03055741)
- 03 Feb 2017 Pharmacodynamics data from a preclinical trial in Alzheimer's disease released by DAE HWA Pharmaceutical